

Discovery of Novel Chemical Series of OXA-48 β-Lactamase Inhibitors by High-Throughput Screening

Barbara Garofalo ¹, Federica Prati ¹, Rosa Buonfiglio ¹, Isabella Coletta ¹, Noemi D'Atanasio ¹, Angela Molteni ², Daniele Caretoni ², Valeria Wanke ², Giorgio Pochetti ³, Roberta Montanari ³, Davide Capelli ³, Claudio Milanese ¹, Francesco Paolo Di Giorgio ¹, and Rosella Ombrato ^{1,*}

¹ Angelini Pharma S.p.A., Global R&D External Innovation, Viale Amelia 70, 00181 Rome, Italy; barbara.garofalo@angelinipharma.com (B.G.); federica.prati@angelinipharma.com (F.P.); rosa.buonfiglio@angelinipharma.com (R.B.); isabella.coletta@angelinipharma.com (I.C.); noemi.datanasio@angelinipharma.com (N.D.); claudio.milanese@angelinipharma.com (C.M.); francescopaolo.digiorgio@angelinipharma.com (F.P.D.G.)

² Axxam SpA Via Meucci 3, Bresso, 20091 Milan, Italy; Angela.Molteni.AM@axxam.com (A.M.); Daniele.Caretoni.DC@axxam.com (D.C.); Valeria.Wanke.VW@axxam.com (V.W.)

³ Consiglio Nazionale delle Ricerche—Istituto di Cristallografia, Via Salaria—km 29.300, Monterotondo, 00015 Rome, Italy; giorgio.pochetti@ic.cnr.it (G.P.); roberta.montanari@ic.cnr.it (R.M.); davide.capelli@ic.cnr.it (D.C.)

* Correspondence: rosella.ombrato@angelinipharma.com

This section provides information on additional tables, schemes and figures mentioned in the main text.

Table of contents

Figure S1. a) Bar chart showing the distribution of the hits across the AC ₅₀ ranges. b) Pie chart showing the frequency of the confirmed OXA-48 inhibitors across the chemical classes.	S2
Figure S2. Detailed binding mode of cocrystal structure of ID3 in complex with OXA48 enzyme from different perspectives.	S2
Figure S3. Detailed binding mode of cocrystal structure of ID2 in complex with OXA48 enzyme from different perspectives.	S2
Table S1. 2D structures of the thirty-eight compounds belonging to SC_2 group showing measurable OXA-48 AC ₅₀ (μM)	S3-S8
Table S2. 2D structures of the thirty-seven compounds belonging to SC_7 group tested in the HTS	S9-S15
Table S3. Statistics of crystallographic data and refinement for crystals of OXA-48 in complex with ID2 and ID3	S16
1H and 13C NMR spectra of final ligands 1-14	S17-S30
HPLC and LC/MS analysis of final ligands 1-14	S31-S44




Figure S1. a) Bar chart showing the distribution of the hits across the AC₅₀ ranges. b) Pie chart showing the frequency of the confirmed OXA-48 inhibitors across the chemical classes.




Figure S2. Detailed binding mode of cocrystal structure of ID3 in complex with OXA48 enzyme from different perspectives. a) thiolate side (rotation with respect to Figure 13b); b) benzoic acid side. Hydrogen bonds, electrostatic and π - π interactions are represented as yellow, purple and grey dashed lines. For the sake of clarity, some portions of the protein have been omitted.

















Figure S3. Detailed binding mode of cocrystal structure of ID2 in complex with OXA48 enzyme from different perspectives. a) benzoic acid side (rotation with respect to Figure 14); b) 4-COOH group side. Hydrogen bonds, electrostatic and π - π interactions are represented as yellow, purple and grey dashed lines. For the sake of clarity, some portions of the protein have been omitted.

Table S1. 2D structures of the thirty-eight compounds belonging to SC_2 group showing measurable OXA-48 AC₅₀ (μ M)







Structure	ID	OXA-48 AC ₅₀ (μ M) ^a	Lower 95% CL	Upper 95% CL	OXA-48 Activity% \pm SE ^b
	ID1	1.14	1.033	1.267	-92.19 \pm 3.86
	ID3	0.723	0.653	0.801	-94.1 \pm 0.48
	ID4	3.17	2.861	3.510	-85.8 \pm 0.09
	ID5	2.88	2.571	3.235	-88.29 \pm 2.58
	ID6	15.7	14.005	17.603	-61.3 \pm 0.08
	ID9	35.6	32.031	39.637	-23.84 \pm 1.45

	ID11	12	9.821	14.600	-58.4±0.96
	ID23	24.8	22.263	27.568	-29.46±3.40
	ID32	16.6	14.556	18.834	-47.99±2.92
	ID33	16.7	15.319	18.167	-62.46±2.46
	ID34	17.1	14.319	20.371	-42.4±1.83
	ID35	18	16.537	19.498	-39.58±0.79
	ID36	21.3	20.106	22.560	-28.58±1.13

	ID37	22.8	18.568	28.044	-53±0.95
	ID38	24	22.175	25.925	-44.71±2.01
	ID39	24.8	23.157	26.621	-32.57±2.09
	ID40	25.2	23.317	27.217	-40.31±2.06
	ID41	25.7	23.844	27.599	-49.33±0.40
	ID42	27.1	24.536	29.830	-44.91±1.84







	ID43	29.2	27.509	31.066	-31.49±0.61
	ID44	32.6	29.950	35.562	-24.72±2.13
	ID45	35.3	29.825	41.715	-42.84±1.26
	ID46	39	36.935	41.132	-22.94±1.81
	ID47	41.4	32.830	52.201	-30.23±1.23
	ID48	43.3	40.817	45.964	-21.52±2.12
	ID49	44.1	37.385	52.077	-40.47±1.99







	ID50	45.2	41.727	48.970	-23.88±0.67
	ID51	47.7	44.752	50.856	-20.12±0.38
	ID52	49.5	44.878	54.659	-22.2±0.09
	ID53	50.5	45.531	55.978	-20.8±2.70
	ID54	61.1	55.378	67.443	-24.39±1.23
	ID55	64.2	55.954	73.696	-26.31±0.64







	ID56	66	61.749	70.617	-28.62±0.26
	ID57	67.1	62.548	71.956	-26.07±0.13
	ID58	76.9	65.211	90.604	-27.29±0.35
	ID59	84	44.511	158.498	-24.82±0.10
	ID60	90	78.204	103.519	-27.4±0.52
	ID61	126.81	110.409	145.643	-17.13±2.75







^aAC₅₀ values were calculated from data points obtained as median of triplicate wells. ^bActivity percent values at 20 µM were calculated as median of triplicate wells and the standard error (SE) is reported.







Table S2. 2D structures of the thirty-seven compounds belonging to SC_7 group tested in the HTS







ID	OXA-48 AC ₅₀ (μ M) ^a	Lower 95% CL	Upper 95% CL	OXA-48 Activity% \pm SE ^b	
	ID2	0.99	0.80	1.22	-93.92 \pm 0.54
	ID30	248.59	176.58	349.95	-13.17 \pm 1.07
	ID31				-25.86 \pm 0.57
	ID62				-16.36 \pm 0.70
	ID63				-12.8 \pm 0.75
	ID64				-12.16 \pm 1.44


	ID65	-10.6±0.52
	ID66	-10.34±0.88
	ID67	-9.89±1.75
	ID68	-9.1±0.90
	ID69	-8.72±0.82
	ID70	-8.16±0.64

	ID71	-7.7±0.67
	ID72	-5.66±3.92
	ID73	-5.39±0.010
	ID74	-5.25±0.76
	ID75	-4.62±2.42
	ID76	-4.41±0.70

	ID77	-4.4±0.05
	ID78	-3.72±1.43
	ID79	-3.64±0.49
	ID80	-3.48±0.69
	ID81	-3.46±3.98
	ID82	-3.2±0.27


	ID83	-2.87±1.47
	ID84	-2.72±0.11
	ID85	-2.61±0.99
	ID86	-2.51±1.74
	ID87	-2.27±0.81
	ID88	-1.6±0.89

	ID89	-1.44±2.67
	ID90	-1.03±0.97
	ID91	-0.543±0.39
	ID92	-0.41±1.14
	ID93	0.07±0.01565712
	ID94	0.39±0.14



ID95

1.19±1.74



ID96

3.62±0.001



^aAC₅₀ values were calculated from data points obtained as median of triplicate wells. ^bActivity percent values at 20 µM were calculated as median of triplicate wells and the standard error (SE) is reported.



Table S3. Statistics of crystallographic data and refinement for crystals of OXA-48 in complex with **ID2** and **ID3**



	ID2	ID3
Data collection		
space group	P2 ₁ 2 ₁ 2 ₁	P2 ₁ 2 ₁ 2 ₁
cell dimension <i>a</i>, <i>b</i>, <i>c</i> [Å]	71.41, 72.63, 125.66	72.47, 73.68, 124.79
wavelength [Å]	1.072	1.072
resolution range [Å]	62.88 - 2.05	51.67 - 1.65
last shell [Å]	2.05 - 2.11	1.65 - 1.68
R_{merge} [%]	8.6 (76.2) ^a	6.8 (32.8) ^a
unique reflections	40846	80899
mean (<i>I</i>)/σ(<i>I</i>)	8.2 (1.8) ^a	11.5 (4.1) ^a
completeness	98.2 (97.7) ^a	99.8 (99.7) ^a
No. of molecules in asymmetric unit	2	2
Refinement		
resolution range [Å]	62.88 - 2.05	51.67 - 1.65
R_{work} [%]	20.6	17.6
R_{free} [%]	24.5	20.7
Bond lengths r.m.s.d. [Å]	0.008	0.009
Bond angles r.m.s.d. [deg]	1.147	1.156
PDB code	7AUX	7AW5



^a The values in parenthesis refer to the outer shell.



¹H and ¹³C NMR spectra of final ligands **1-14**


















































HPLC and LC/MS analysis of final ligands 1-14



Compound 1




Compound 2




Compound 3





Compound 4





S:\Angelini\An...16-1768-08-11.D Injection 1 Function 1 (1768-08-1) MS + spectrum 5.08..5.43





Compound 5




Compound 6




Compound 7



Compound 8




Compound 9




Compound 10

\Scs-pc005\ez...82-17-P_15MIN.D Injection 1 VWD A, Wavelength=254 nm Chromatogram




\Scs-pc005\ez...82-17-P_15MIN.D Injection 1 Function 1 (1582-17-P_15min) MS + spectrum 7.35




Compound 11


\Scs-pc005\ez...-ACIDIC_15MIN.D Injection 1 VWD A, Wavelength=254 nm Chromatogram




\Scs-pc005\ez...-ACIDIC_15MIN.D Injection 1 Function 1 (15...9-acidic_15min) MS + spectrum 8.34



Compound 12



Compound 13



Compound 14

